felodipine has been researched along with Angor Pectoris in 30 studies
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.
felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary objective of this randomized, double-blind, parallel group trial was to compare the antianginal and antiischemic efficacy of a combination tablet of felodipine-metoprolol 10/100 mg once daily with both drugs given separately once daily in patients with stable effort-induced angina pectoris." | 9.09 | Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: a multicenter parallel group study. The TRAFFIC Study Group. ( Egstrup, K; Ellström, J; Emanuelsson, H; Forsby, M; Glud, T; Nikus, K; Pater, C; Scheibel, M; Tisell, A; Tötterman, KJ, 1999) |
| "The study aimed to compare the addition of felodipine to metoprolol, and of the replacement of metoprolol by felodipine, with continuation of metoprolol, in patients with angina pectoris despite optimal beta-blockade." | 9.08 | Addition of felodipine to metoprolol vs replacement of metoprolol by felodipine in patients with angina pectoris despite adequate beta-blockade. Results of the Felodipine ER and Metoprolol CR in Angina (FEMINA) Study. Working Group on Cardiovascular Resea ( Bernink, P; Bosma, A; Dunselman, P; Kragten, H; Liem, AH; Verdel, G, 1997) |
| "The additional efficacy, duration of action and tolerability of felodipine were evaluated in patients with stable angina pectoris and a positive stress test who were already receiving therapy with a beta-adrenergic blocker." | 9.08 | Felodipine in addition to beta-adrenergic blockade for angina pectoris. a multicentre, randomized, placebo-controlled trial. ( Ostergaard, O; Rønnevik, PK; Silke, B, 1995) |
| "The effects of single doses of felodipine (5 and 10 mg) and nifedipine (10 and 20 mg) on chronic stable effort angina pectoris were assessed in a placebo-controlled, double-blind, crossover study of 24 patients receiving beta blockers and short-acting nitroglycerin." | 9.07 | Effects of felodipine versus nifedipine on exercise tolerance in stable angina pectoris. ( Aberg, A; Ekelund, LG; Ulvenstam, G; Walldius, G, 1994) |
| "We compared the antianginal and antiischemic effect and tolerability of four different doses of felodipine extended-release (ER) tablets with placebo in patients with stable effort-induced angina pectoris treated with beta-blocker [metoprolol controlled release (CR) 100 mg once daily, o." | 9.07 | Felodipine versus placebo in stable effort-induced angina pectoris in patients inadequately controlled with metoprolol--a dose-finding study. ( Ahlström, P; Angman, K; Emanuelsson, H; Kujacic, V; Lundkvist, L; Rosenqvist, U; Tisell, A, 1994) |
| " To assess the efficacy and safety of the calcium channel blocker, felodipine, and isosorbide mononitrate (ISMN), as adjunct to optimal beta-blocker therapy in elderly patients, a placebo-controlled, double-blind study was conducted in 46 patients, aged between 65 and 80 years, with documented stress-induced angina pectoris and myocardial ischemia." | 9.07 | Comparison between felodipine and isosorbide mononitrate as adjunct to beta blockade in patients > 65 years of age with angina pectoris. ( de Vries, RJ; Dunselman, PH; Lie, KI; van den Heuvel, AF; van Veldhuisen, DJ; Wielenga, RP, 1994) |
| "To investigate the antianginal efficacy, duration of action and tolerability of 2 doses of the new calcium antagonist felodipine, 15 patients (14 men and 1 woman, mean age 62 years) with stable exertional angina pectoris and angiographically demonstrated coronary artery disease were randomly given felodipine, 5 and 10 mg, and placebo on 3 different days." | 9.06 | Acute effects of felodipine in exertional angina pectoris. ( Ceschia, G; Pandullo, C; Pivotti, F; Pollavini, G; Scardi, S, 1988) |
| "We studied the effects of adding felodipine to beta-adrenoceptor blockade on haemodynamics and exercise capacity in 14 patients with stable angina pectoris using a placebo controlled double-blind crossover protocol." | 9.06 | Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris. ( Routledge, PA; Sheridan, DJ; Sheridan, JV; Thomas, P, 1987) |
| "In the treatment of Prinzmetal's angina, their antivasospastic properties account for their therapeutic effectiveness." | 7.78 | The evolving role of calcium channel blockers in the treatment of angina pectoris: focus on felodipine. ( Gradman, AH, 1995) |
| "To examine the antianginal effects of felodipine, a new calcium antagonist, 8 patients with coronary artery disease and exertional angina pectoris were studied." | 7.66 | Hemodynamic effects of felodipine at rest and during exercise in exertional angina pectoris. ( De Coster, PM; Detry, JM; Renkin, J, 1983) |
| " Four hours after dosing with both felodipine doses, only 5 patients discontinued the exercise test because of greater than 2 mm of ST-segment depression, whereas 10 continued until exhaustion (p less than 0." | 6.67 | Twenty-four-hour activity of felodipine extended release in chronic stable angina pectoris. ( Alberti, D; Di Bello, V; Giusti, C; Santoro, G; Savonitto, S, 1991) |
| "Felodipine has overall a modest but significant anti-anginal benefit when combined with a beta-blocker." | 6.67 | The effects of felodipine in angina pectoris. ( Barbour, MP; Fox, Y; Lawrie, TD; Lorimer, AR; MacFarlane, P; Pringle, S, 1990) |
| "The chemistry, pharmacology, pharmacokinetics, clinical uses, adverse effects, and dosage of felodipine and isradipine are reviewed." | 6.38 | Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension. ( Symes, LR; Walton, T, 1993) |
| "Felodipine, a dihydropyridine calcium-channel antagonist, significantly reduces systolic and diastolic blood pressure (BP) in patients with hypertension and has been associated with beneficial hemodynamic effects in patients with chronic stable angina pectoris or congestive heart failure (CHF)." | 6.16 | Felodipine: a new dihydropyridine calcium-channel antagonist. ( Lopez, LM; Yedinak, KC, 1991) |
| "The primary objective of this randomized, double-blind, parallel group trial was to compare the antianginal and antiischemic efficacy of a combination tablet of felodipine-metoprolol 10/100 mg once daily with both drugs given separately once daily in patients with stable effort-induced angina pectoris." | 5.09 | Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: a multicenter parallel group study. The TRAFFIC Study Group. ( Egstrup, K; Ellström, J; Emanuelsson, H; Forsby, M; Glud, T; Nikus, K; Pater, C; Scheibel, M; Tisell, A; Tötterman, KJ, 1999) |
| "The additional efficacy, duration of action and tolerability of felodipine were evaluated in patients with stable angina pectoris and a positive stress test who were already receiving therapy with a beta-adrenergic blocker." | 5.08 | Felodipine in addition to beta-adrenergic blockade for angina pectoris. a multicentre, randomized, placebo-controlled trial. ( Ostergaard, O; Rønnevik, PK; Silke, B, 1995) |
| "The study aimed to compare the addition of felodipine to metoprolol, and of the replacement of metoprolol by felodipine, with continuation of metoprolol, in patients with angina pectoris despite optimal beta-blockade." | 5.08 | Addition of felodipine to metoprolol vs replacement of metoprolol by felodipine in patients with angina pectoris despite adequate beta-blockade. Results of the Felodipine ER and Metoprolol CR in Angina (FEMINA) Study. Working Group on Cardiovascular Resea ( Bernink, P; Bosma, A; Dunselman, P; Kragten, H; Liem, AH; Verdel, G, 1997) |
| "We compared the antianginal and antiischemic effect and tolerability of four different doses of felodipine extended-release (ER) tablets with placebo in patients with stable effort-induced angina pectoris treated with beta-blocker [metoprolol controlled release (CR) 100 mg once daily, o." | 5.07 | Felodipine versus placebo in stable effort-induced angina pectoris in patients inadequately controlled with metoprolol--a dose-finding study. ( Ahlström, P; Angman, K; Emanuelsson, H; Kujacic, V; Lundkvist, L; Rosenqvist, U; Tisell, A, 1994) |
| " To assess the efficacy and safety of the calcium channel blocker, felodipine, and isosorbide mononitrate (ISMN), as adjunct to optimal beta-blocker therapy in elderly patients, a placebo-controlled, double-blind study was conducted in 46 patients, aged between 65 and 80 years, with documented stress-induced angina pectoris and myocardial ischemia." | 5.07 | Comparison between felodipine and isosorbide mononitrate as adjunct to beta blockade in patients > 65 years of age with angina pectoris. ( de Vries, RJ; Dunselman, PH; Lie, KI; van den Heuvel, AF; van Veldhuisen, DJ; Wielenga, RP, 1994) |
| "The effects of single doses of felodipine (5 and 10 mg) and nifedipine (10 and 20 mg) on chronic stable effort angina pectoris were assessed in a placebo-controlled, double-blind, crossover study of 24 patients receiving beta blockers and short-acting nitroglycerin." | 5.07 | Effects of felodipine versus nifedipine on exercise tolerance in stable angina pectoris. ( Aberg, A; Ekelund, LG; Ulvenstam, G; Walldius, G, 1994) |
| "The acute effects on exercise tolerance and electrocardiographic ischaemia of felodipine and diltiazem, alone or in combination, were investigated in 12 patients with documented stable effort-induced angina pectoris." | 5.07 | Acute effects on exercise tolerance of felodipine and diltiazem, alone and in combination, in stable effort angina. ( Fazzini, P; Pollavini, G; Pucci, PD; Zerauscheck, M, 1991) |
| "The antianginal properties and the duration of action of two doses of felodipine, a dihydropyridine calcium antagonist with a vascular:myocardial potency ratio approximating 100:1, were investigated in 15 patients suffering from disabling effort angina pectoris with reproducible exercise tolerance." | 5.06 | Increased exercise tolerance and reduced electrocardiographic ischaemia 3 and 12 hours after oral felodipine in effort angina. ( Benemio, G; Boldrini, F; Gatteschi, C; Guerrieri, M; Pollavini, G; Porcellati, C; Verdecchia, P, 1989) |
| "We studied the effects of adding felodipine to beta-adrenoceptor blockade on haemodynamics and exercise capacity in 14 patients with stable angina pectoris using a placebo controlled double-blind crossover protocol." | 5.06 | Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris. ( Routledge, PA; Sheridan, DJ; Sheridan, JV; Thomas, P, 1987) |
| "The effects of felodipine on haemodynamics and exercise capacity have been studied in patients with angina pectoris." | 5.06 | Felodipine in ischaemic heart disease. ( Sheridan, DJ; Sheridan, JV; Thomas, P, 1987) |
| "To investigate the antianginal efficacy, duration of action and tolerability of 2 doses of the new calcium antagonist felodipine, 15 patients (14 men and 1 woman, mean age 62 years) with stable exertional angina pectoris and angiographically demonstrated coronary artery disease were randomly given felodipine, 5 and 10 mg, and placebo on 3 different days." | 5.06 | Acute effects of felodipine in exertional angina pectoris. ( Ceschia, G; Pandullo, C; Pivotti, F; Pollavini, G; Scardi, S, 1988) |
| "In the treatment of Prinzmetal's angina, their antivasospastic properties account for their therapeutic effectiveness." | 3.78 | The evolving role of calcium channel blockers in the treatment of angina pectoris: focus on felodipine. ( Gradman, AH, 1995) |
| "Felodipine is a vascular-selective, dihydropyridine calcium antagonist previously investigated as a conventional tablet formulation administered twice daily." | 3.77 | Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. ( Faulds, D; Todd, PA, 1992) |
| "To examine the antianginal effects of felodipine, a new calcium antagonist, 8 patients with coronary artery disease and exertional angina pectoris were studied." | 3.66 | Hemodynamic effects of felodipine at rest and during exercise in exertional angina pectoris. ( De Coster, PM; Detry, JM; Renkin, J, 1983) |
| " Four hours after dosing with both felodipine doses, only 5 patients discontinued the exercise test because of greater than 2 mm of ST-segment depression, whereas 10 continued until exhaustion (p less than 0." | 2.67 | Twenty-four-hour activity of felodipine extended release in chronic stable angina pectoris. ( Alberti, D; Di Bello, V; Giusti, C; Santoro, G; Savonitto, S, 1991) |
| "Felodipine has overall a modest but significant anti-anginal benefit when combined with a beta-blocker." | 2.67 | The effects of felodipine in angina pectoris. ( Barbour, MP; Fox, Y; Lawrie, TD; Lorimer, AR; MacFarlane, P; Pringle, S, 1990) |
| "Felodipine has antianginal effects but these are limited and seem less than those of other related compounds." | 2.66 | The effects of treatment with felodipine as a single agent in coronary artery disease. ( Chan-Wah-Hak, NS; Jennings, K; Metcalfe, MJ, 1989) |
| "The chemistry, pharmacology, pharmacokinetics, clinical uses, adverse effects, and dosage of felodipine and isradipine are reviewed." | 2.38 | Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension. ( Symes, LR; Walton, T, 1993) |
| "For many years the pharmacological treatment of heart failure patients was based on the increase in inotropism through the digitalis and on the reduction in sodium-water retention through diuretics, while less importance was given to the improvement of the afterload." | 1.29 | [The role of ACE inhibitors in heart failure. Lessons of CONSENSUS, SOLVD and V-HeFTII]. ( Dessì-Fulgheri, P; Paci, MV; Rappelli, A, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (26.67) | 18.7374 |
| 1990's | 20 (66.67) | 18.2507 |
| 2000's | 1 (3.33) | 29.6817 |
| 2010's | 1 (3.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Navadiya, K | 1 |
| Tiwari, S | 1 |
| Mann, S | 1 |
| Detry, JM | 1 |
| De Coster, PM | 1 |
| Renkin, J | 1 |
| Tweddel, AC | 1 |
| Johnsson, G | 1 |
| Pringle, TH | 1 |
| Murray, RG | 1 |
| Hutton, I | 1 |
| Emanuelsson, H | 3 |
| Hjalmarson, A | 1 |
| Holmberg, S | 1 |
| Waagstein, F | 1 |
| Ahlström, P | 1 |
| Kujacic, V | 1 |
| Lundkvist, L | 1 |
| Rosenqvist, U | 1 |
| Tisell, A | 2 |
| Angman, K | 1 |
| Gradman, AH | 1 |
| Dessì-Fulgheri, P | 1 |
| Paci, MV | 1 |
| Rappelli, A | 1 |
| Koolen, JJ | 1 |
| Van Wezel, HB | 1 |
| Piek, J | 1 |
| van Liebergen, R | 1 |
| Swaan, A | 1 |
| Visser, CA | 1 |
| de Vries, RJ | 1 |
| Dunselman, PH | 1 |
| van Veldhuisen, DJ | 1 |
| van den Heuvel, AF | 1 |
| Wielenga, RP | 1 |
| Lie, KI | 1 |
| Ekelund, LG | 1 |
| Ulvenstam, G | 1 |
| Walldius, G | 1 |
| Aberg, A | 1 |
| Walton, T | 1 |
| Symes, LR | 1 |
| Mazzotta, G | 1 |
| Falcidieno, M | 1 |
| Ravera, E | 1 |
| Vecchio, C | 1 |
| Rønnevik, PK | 1 |
| Silke, B | 1 |
| Ostergaard, O | 1 |
| Koenig, W | 1 |
| Höher, M | 1 |
| Dunselman, P | 1 |
| Liem, AH | 1 |
| Verdel, G | 1 |
| Kragten, H | 1 |
| Bosma, A | 1 |
| Bernink, P | 1 |
| Tiberti, G | 1 |
| Bossi, M | 1 |
| Egstrup, K | 1 |
| Nikus, K | 1 |
| Ellström, J | 1 |
| Glud, T | 1 |
| Pater, C | 1 |
| Scheibel, M | 1 |
| Tötterman, KJ | 1 |
| Forsby, M | 1 |
| Todd, PA | 1 |
| Faulds, D | 1 |
| Lorimer, AR | 2 |
| Macfarlane, P | 2 |
| Pringle, S | 2 |
| Barbour, MP | 2 |
| Fox, Y | 2 |
| Lawrie, TD | 2 |
| Yedinak, KC | 1 |
| Lopez, LM | 1 |
| Santoro, G | 1 |
| Savonitto, S | 2 |
| Di Bello, V | 1 |
| Alberti, D | 1 |
| Giusti, C | 1 |
| Pucci, PD | 1 |
| Pollavini, G | 3 |
| Zerauscheck, M | 1 |
| Fazzini, P | 1 |
| Sangiorgio, P | 1 |
| Di Pasquale, G | 1 |
| Urbinati, S | 1 |
| Rubboli, A | 1 |
| Cavallotti, G | 1 |
| Pinelli, G | 1 |
| Bracchetti, D | 1 |
| Metcalfe, MJ | 1 |
| Chan-Wah-Hak, NS | 1 |
| Jennings, K | 1 |
| Verdecchia, P | 1 |
| Gatteschi, C | 1 |
| Benemio, G | 1 |
| Guerrieri, M | 1 |
| Boldrini, F | 1 |
| Porcellati, C | 1 |
| Sheridan, JV | 2 |
| Thomas, P | 2 |
| Routledge, PA | 1 |
| Sheridan, DJ | 2 |
| Scardi, S | 1 |
| Pandullo, C | 1 |
| Pivotti, F | 1 |
| Ceschia, G | 1 |
5 reviews available for felodipine and Angor Pectoris
| Article | Year |
|---|---|
Pharmacology, Efficacy and Safety of Felodipine with a Focus on Hypertension and Angina Pectoris.
Topics: Angina Pectoris; Animals; Antihypertensive Agents; Calcium Channel Blockers; Felodipine; Humans; Hyp | 2015 |
The evolving role of calcium channel blockers in the treatment of angina pectoris: focus on felodipine.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina Pectoris, Variant; Angina, Unstable; Calcium Ch | 1995 |
Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension.
Topics: Angina Pectoris; Animals; Drug Interactions; Felodipine; Heart Failure; Hemodynamics; Humans; Hypert | 1993 |
Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.
Topics: Angina Pectoris; Cardiomegaly; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Interact | 1992 |
Felodipine: a new dihydropyridine calcium-channel antagonist.
Topics: Angina Pectoris; Animals; Blood Pressure; Double-Blind Method; Felodipine; Heart Failure; Humans; Hy | 1991 |
22 trials available for felodipine and Angor Pectoris
| Article | Year |
|---|---|
Felodipine versus placebo in stable effort-induced angina pectoris in patients inadequately controlled with metoprolol--a dose-finding study.
Topics: Aged; Angina Pectoris; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, | 1994 |
The evolving role of calcium channel blockers in the treatment of angina pectoris: focus on felodipine.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina Pectoris, Variant; Angina, Unstable; Calcium Ch | 1995 |
Effects of intracoronary felodipine versus nifedipine on left ventricular contractility and coronary sinus blood flow in stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Coronary Circulation; Coronary Vessels; Felodipine; Humans; Injections | 1994 |
Comparison between felodipine and isosorbide mononitrate as adjunct to beta blockade in patients > 65 years of age with angina pectoris.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Cross-Over Studies; Delayed-Action Preparations; | 1994 |
Effects of felodipine versus nifedipine on exercise tolerance in stable angina pectoris.
Topics: Analysis of Variance; Angina Pectoris; Blood Pressure; Double-Blind Method; Exercise; Felodipine; Fe | 1994 |
[Efficacy and tolerability of felodipine and nifedipine in stable angina refractory to beta-blocker therapy].
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Cross-Over Studies; Do | 1996 |
Felodipine in addition to beta-adrenergic blockade for angina pectoris. a multicentre, randomized, placebo-controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Double-Blind Me | 1995 |
Felodipine and amlodipine in stable angina pectoris: results of a randomized double-blind crossover trial.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blocker | 1997 |
Addition of felodipine to metoprolol vs replacement of metoprolol by felodipine in patients with angina pectoris despite adequate beta-blockade. Results of the Felodipine ER and Metoprolol CR in Angina (FEMINA) Study. Working Group on Cardiovascular Resea
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Dou | 1997 |
Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: a multicenter parallel group study. The TRAFFIC Study Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Double-Blind Me | 1999 |
Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.
Topics: Angina Pectoris; Cardiomegaly; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Interact | 1992 |
Antianginal effect of felodipine.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Double-Blind Method; Drug Therapy, Combination; Electr | 1990 |
Felodipine: a new dihydropyridine calcium-channel antagonist.
Topics: Angina Pectoris; Animals; Blood Pressure; Double-Blind Method; Felodipine; Heart Failure; Humans; Hy | 1991 |
Twenty-four-hour activity of felodipine extended release in chronic stable angina pectoris.
Topics: Aged; Angina Pectoris; Chronic Disease; Delayed-Action Preparations; Double-Blind Method; Drug Admin | 1991 |
Acute effects on exercise tolerance of felodipine and diltiazem, alone and in combination, in stable effort angina.
Topics: Angina Pectoris; Blood Pressure; Diltiazem; Double-Blind Method; Drug Therapy, Combination; Electroc | 1991 |
The effects of felodipine in angina pectoris.
Topics: Adult; Angina Pectoris; Blood Pressure; Double-Blind Method; Electrocardiography; Exercise Test; Fel | 1990 |
Felodipine in chronic stable angina: a randomized, double-blind, placebo-controlled, crossover study.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Double-Blind Method; Exercise Test; Felodipine; Heart | 1990 |
The effects of treatment with felodipine as a single agent in coronary artery disease.
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Drug Administration Sch | 1989 |
Increased exercise tolerance and reduced electrocardiographic ischaemia 3 and 12 hours after oral felodipine in effort angina.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Coronary Circulation; Electrocardiography; Exerc | 1989 |
Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Double-Blind Method; Exercise Test; Felodipi | 1987 |
Felodipine in ischaemic heart disease.
Topics: Adult; Aged; Angina Pectoris; Antihypertensive Agents; Clinical Trials as Topic; Coronary Disease; D | 1987 |
Acute effects of felodipine in exertional angina pectoris.
Topics: Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Exercise Test; Felod | 1988 |
6 other studies available for felodipine and Angor Pectoris
| Article | Year |
|---|---|
Dihydropyridines, felodipine, and PHARMAC.
Topics: Angina Pectoris; Calcium Channel Blockers; Dihydropyridines; Drug Approval; Drug Industry; Felodipin | 2005 |
Hemodynamic effects of felodipine at rest and during exercise in exertional angina pectoris.
Topics: Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Coronary Circulatio | 1983 |
The systemic and coronary haemodynamic effects of felodipine in patients with coronary heart disease.
Topics: Adult; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Cardiac Catheterization; Coronary C | 1983 |
Effects of felodipine on systemic and coronary haemodynamics in patients with angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Cardiac Pacing, Artificial; Coronary Circulation; Electrocardiography; | 1984 |
[The role of ACE inhibitors in heart failure. Lessons of CONSENSUS, SOLVD and V-HeFTII].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Clinical | 1994 |
[Stable angina pectoris: what is the role of calcium antagonists?].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Calcium Channel Blockers; Clinical Trials as | 1997 |